{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:53:05Z","timestamp":1775713985996,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.clineuro.2009.07.018","type":"journal-article","created":{"date-parts":[[2009,9,4]],"date-time":"2009-09-04T07:08:40Z","timestamp":1252048120000},"page":"742-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: The ROPI-PARK Study"],"prefix":"10.1016","volume":"111","author":[{"given":"F.","family":"Valldeoriola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cobaleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2009.07.018_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archneur.62.3.353","article-title":"Molecular pathogenesis of Parkinson's disease","volume":"62","author":"Eriksen","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2009.07.018_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.clineuro.2009.07.018_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clineuro.2009.07.018_bib4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson's disease cohort","volume":"130","author":"Williams-Gray","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.clineuro.2009.07.018_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/mds.20525","article-title":"Medicine-taking behaviour: implications of suboptimal compliance in Parkinson's disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2009.07.018_bib6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/14656566.7.13.1715","article-title":"Levodopa, motor fluctuations and dyskinesia in Parkinson's disease","volume":"13","author":"Muller","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 2","key":"10.1016\/j.clineuro.2009.07.018_bib7","first-page":"S36","article-title":"Management of response fluctuations; practical guidelines","volume":"51","author":"Djaldetti","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2009.07.018_bib8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or l-dopa, The 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clineuro.2009.07.018_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1212\/WNL.48.2.363","article-title":"Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group","volume":"48","author":"Rinne","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2009.07.018_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/mds.10642","article-title":"Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations","volume":"19","author":"Marras","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2009.07.018_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1212\/01.wnl.0000265593.34438.00","article-title":"Risk factors for somnolence, edema, and hallucinations in early Parkinson disease","volume":"69","author":"Biglan","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2009.07.018_bib12","series-title":"ECDEU assessment manual for psychopharmacology, revised (DHEW Publ No ADM 76-338)","article-title":"Clinical global impressions","author":"Guy","year":"1976"},{"key":"10.1016\/j.clineuro.2009.07.018_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2009.07.018_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.870020201","article-title":"Young onset Parkinson's disease","volume":"2","author":"Quinn","year":"1987","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2009.07.018_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.febslet.2008.01.028","article-title":"D2\/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways","volume":"582","author":"Chen","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clineuro.2009.07.018_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clineuro.2009.07.018_bib17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/archneur.61.12.1966","article-title":"Initial treatment of Parkinson disease","volume":"61","author":"Weiner","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2009.07.018_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0404.2002.01343.x","article-title":"Dosing with ropinirole in a clinical setting","volume":"206","author":"Korczyn","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clineuro.2009.07.018_bib19","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","article-title":"Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group","volume":"55","author":"Sethi","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2009.07.018_bib20","first-page":"101","article-title":"A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease","volume":"21","author":"Brooks","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clineuro.2009.07.018_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846709001851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846709001851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:26:58Z","timestamp":1759588018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846709001851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0303846709001851"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2009.07.018","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: The ROPI-PARK Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2009.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}